{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BXVNPIAN/0cc33c99-2397-4fb3-90c2-2d01b3cfa647/PDF","dcterms:extent":"2040 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-BXVNPIAN/bfcac632-7658-4685-b5ef-f3fe1f5740c6/TEXT","dcterms:extent":"11 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-BXVNPIAN","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:SPR-WQVGMCSC"},{"@xml:lang":"sl","#text":"Acta dermatovenerologica Alpina, Pannonica et Adriatica"}],"dcterms:issued":"2000","dc:creator":["Krajnc, Ivan","Lukanovič, Kamilo","Prelog, Ida"],"dc:format":[{"@xml:lang":"sl","#text":"številka:3"},{"@xml:lang":"sl","#text":"letnik:9"},{"@xml:lang":"sl","#text":"str. 110-112"}],"dc:identifier":["COBISSID:12158425","ISSN:1318-4458","URN:URN:NBN:SI:doc-BXVNPIAN"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Slovene Welding Society"},"dc:subject":[{"@xml:lang":"sl","#text":"Arthritis, psoriatic"},{"@xml:lang":"sl","#text":"Cyclosporine"},{"@xml:lang":"sl","#text":"Drug therapy"},{"@xml:lang":"sl","#text":"psoriatični artritis"},{"@xml:lang":"sl","#text":"Treatment outcome"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Treatment of psoriatic arthritis with cyclosporin A|"},"dc:description":{"@xml:lang":"sl","#text":"The purpose of this study was to determine the efficacy and toxicity of cyclosporin A (CsA) in treatment of patients affected with psoriatic arthritis(PsA). Methods: This study includes 11 patients with PsA. Clinical and functional parameters are assessed: Ritchie Index, duration of the morningstiffness of joints in minutes, and pain. Laboratory values in serum were checked: SR, CRP, urea, creatinin, cholesterol, trigliceride, electrolyte, and liver enzymes. Measurements of blood pressure were taken monthly. Results: With a therapeutic dose of CsA 3 mg/kg/daily we noticed an improvement of clinical parameters, but not of laboratory values. Conclusion: The investigation showed that CsA in the dosis of 3 mg/kg/daily was efficient and safe in the treatment of PsA"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-BXVNPIAN","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-BXVNPIAN"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-BXVNPIAN/0cc33c99-2397-4fb3-90c2-2d01b3cfa647/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Združenje slovenskih dermatovenerologov"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-BXVNPIAN/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-BXVNPIAN"}}}}